Note to readers: The Daily Edition will not be published Dec. 23 through Jan. 1. Look for it again in your inbox on Jan. 2.

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

A lawsuit forced the FDA to reassess its ruling on the availability of tirzepatide, the active ingredient in the popular drugs Mounjaro and Zepbound from Eli Lilly. As a result, the agency also told ...

Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug ...

Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.

The U.S.-listed shares of Novo Nordisk A.S. were plunging toward their worst day in decades on Friday after the results from a late-stage trial showed that the Danish company's new weight-loss drug ...

Novo Nordisk's trial for its obesity drug CagriSema resulted in a lower-than-expected weight loss of 22.7%, impacting its market value. Despite these results, Novo remains optimistic about further ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

FedEx Corp shares increased 9% in Friday's premarket session after the package delivery company outlined plans to spin off its FedEx Freight trucking business Eli Lilly s ...

One out of 20 prescriptions written in the U.S. is for a GLP-1 drug. US doctors write billions of prescriptions each year.

Nestle just rolled out a new protein shot drink that it says will help people looking to lose weight manage their hunger and ...